MX2021003938A - Composicion para prevenir o tratar un tumor benigno. - Google Patents

Composicion para prevenir o tratar un tumor benigno.

Info

Publication number
MX2021003938A
MX2021003938A MX2021003938A MX2021003938A MX2021003938A MX 2021003938 A MX2021003938 A MX 2021003938A MX 2021003938 A MX2021003938 A MX 2021003938A MX 2021003938 A MX2021003938 A MX 2021003938A MX 2021003938 A MX2021003938 A MX 2021003938A
Authority
MX
Mexico
Prior art keywords
peptide
benign tumor
analog
composition
inducing
Prior art date
Application number
MX2021003938A
Other languages
English (en)
Spanish (es)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of MX2021003938A publication Critical patent/MX2021003938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021003938A 2018-10-05 2019-10-04 Composicion para prevenir o tratar un tumor benigno. MX2021003938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018190461 2018-10-05
PCT/JP2019/039383 WO2020071551A1 (ja) 2018-10-05 2019-10-04 良性腫瘍の予防または治療薬

Publications (1)

Publication Number Publication Date
MX2021003938A true MX2021003938A (es) 2021-08-11

Family

ID=70054693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003938A MX2021003938A (es) 2018-10-05 2019-10-04 Composicion para prevenir o tratar un tumor benigno.

Country Status (10)

Country Link
US (1) US12440546B2 (https=)
EP (1) EP3865146A4 (https=)
JP (1) JP7393752B2 (https=)
KR (1) KR102901715B1 (https=)
CN (1) CN113395976B (https=)
AU (1) AU2019352354B2 (https=)
CA (1) CA3115240A1 (https=)
MX (1) MX2021003938A (https=)
TW (1) TWI851607B (https=)
WO (1) WO2020071551A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4149953A4 (en) * 2020-05-12 2024-06-26 Lg Chem, Ltd. MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
CN120484057A (zh) * 2025-05-07 2025-08-15 宁夏医科大学总医院 一种治疗结直肠息肉的短肽及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP940432B1 (en) 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ATE340560T1 (de) * 1999-05-24 2006-10-15 Introgen Therapeutics Inc Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
CN101098708A (zh) * 2004-11-10 2008-01-02 胡布雷希特实验室 通过抑制Notch途径激活治疗肠腺瘤和/或腺癌
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
ES2679127T3 (es) * 2007-12-05 2018-08-22 International Institute Of Cancer Immunology, Inc. Composición vacunal contra el cáncer
WO2012037551A2 (en) * 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
JP6117515B2 (ja) 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
WO2013096297A1 (en) * 2011-12-20 2013-06-27 North Carolina State University Methods to reduce polyposis and colorectal cancer
MY171854A (en) * 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
CN107074970B (zh) * 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
MX392470B (es) 2014-12-11 2025-03-24 Int Inst Cancer Immunology Inc Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
JP6515182B2 (ja) * 2015-05-20 2019-05-15 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
LT3377516T (lt) * 2015-11-20 2022-09-26 Memorial Sloan Kettering Cancer Center Kompozicija vėžiui gydyti
EP3604325A4 (en) * 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
JP6741049B2 (ja) 2018-08-07 2020-08-19 カシオ計算機株式会社 注文処理装置及びプログラム

Also Published As

Publication number Publication date
KR102901715B1 (ko) 2025-12-18
AU2019352354B2 (en) 2025-07-03
US20220008528A1 (en) 2022-01-13
JP7393752B2 (ja) 2023-12-07
JPWO2020071551A1 (ja) 2021-09-24
US12440546B2 (en) 2025-10-14
KR20210073540A (ko) 2021-06-18
TW202027777A (zh) 2020-08-01
TWI851607B (zh) 2024-08-11
EP3865146A1 (en) 2021-08-18
WO2020071551A1 (ja) 2020-04-09
CA3115240A1 (en) 2020-04-09
EP3865146A4 (en) 2022-06-29
CN113395976B (zh) 2025-11-21
AU2019352354A1 (en) 2021-05-13
CN113395976A (zh) 2021-09-14
NZ774631A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
MX2021003938A (es) Composicion para prevenir o tratar un tumor benigno.
DOP2023000285A (es) Restos de administración terapéutica novedosos y usos de estos
ECSP21038390A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr
CO2022002781A2 (es) Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
MX2021009673A (es) Moduladores de ror-gamma.
AR057868A1 (es) Metodos en los que se usa 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona para el tratamiento de ciertas leucemias
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2018012901A (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
MX2019008755A (es) Variantes de hsd17b13 y usos de las mismas.
MX2019013756A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
DOP2016000316A (es) Dinucleótidos cíclicos como moduladores de sting
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2021007241A (es) Acido ribonucleico (arn) que codifica para una proteina.
UY36674A (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
NI201800039A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
CO2019009722A2 (es) Dendrímeros terapéuticos
NI201800040A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
MX393601B (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
UY36518A (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
MX2021004566A (es) Compuestos terapeuticos.
MX2023009976A (es) Compuestos de pladienolida y su uso.